*Based on commercial patients, early access patients, and clinical trial participants through May 2022.
†Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
‡Based on commercial patients in the US (including Puerto Rico) through May 2022.